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Is2121 Recombinant bacterial vaccine carriers 
C. Locht. INSERM U447, lnsfitut Pasteur de Lille, Lille, France 
Objectives: Mucosal infections often induce better and longer- 
lasting protection than parented vaccination. Therefore, several 
attenuated bacterial live vectors have been developed, mostly adapted 
for the gastrointestinal tract. However, oral vaccination has several 
disadvantages that may perhaps be overcome by intranasal adminis- 
tration. We have therefore developed an attenuated live Bordetella 
pertussis vector specifically adapted for intranasal immunization. 
Methods: The gene coding for pertussis toxin, the major 
virulence factor of B. pertussis, was deleted from the chromosome by 
homologous recombination. Heterologous antigens were fused to the 
filamentous hemagglutinin, the major secreted protein of the 
organism, through the construction of chimeric genes. Mice were 
then infected with the recombinant attenuated or non-attenuated 
strains, and colonization as well as immunogenicity were measured. 
The mice were then challenged with either virulent B. pertussis or 
the microorganisms corresponding to the heterologous antigens, and 
protection was evaluated. 
Results: The deletion of the pertussis toxin gene did not 
dramatically alter colonization. The attenuated strains were at least as 
immunogenic as the non-attenuated strains, and a single intranasal 
administration of an attenuated recombinant strain was able to protect 
against both B. pertussis and heterologous challenges. 
Conclusions: Recombinant attenuated B. pertussis can be used to 
protect against B. pertnssis and heterologous challenges after a single 
intranasal immunization. 
Vaccination against stomach ulcers caused by 
Helicobacter pylori 
R. Rappuoli. IRIS, Chirofi S.p.A., Siena, Italy 
Helicobacterpylori is a ‘slow’ bacterial pathogen that affects about 50% 
of the population in developed countries and about 80% of the 
population in the developing world. The most common pathology 
associated with H .  pylori infection is chronic active gastritis and peptic 
ulceration, although long-term chronic infection is a risk factor for 
gastric adenocarcinoma and lymphoma. While infection is usually 
acquired early in life, only decades later does severe pathology appear. 
During these long periods of incubation, the host mounts a vigorous 
immune response against H .  pylori which fails to resolve the infection 
and may contribute to the severity of the disease. Evidence has 
accumulated indicating a role for a polarized T-helper 1 cell response 
in the gastric pathology induced by H .  pylori. Furthermore, a 
pathogenicity island in type 1 H .  pylori strains has been shown to be 
responsible for H .  pylori-induced inflammation. 
H .  pylori infection is currently treated with an association of anti- 
secretory drugs and antibiotics. However, recent advances in animal 
models have provided the rationale for the entry into human clinical 
trials of an H .  pylori vaccine. The challenge of the coming years will 
be to identify a vaccine formulation to be tested in clinical trials and 
to identify the target population of a candidate H .  pylori vaccine, as 
well as to test the efficacy of therapeutic immunization. 
Data on the progress of vaccine development will be presented. 
Progress of vaccine adoption into national 
immunizations programs 
M. Miller. Children’s Vaccine Initiative, Geneva, Switzerland 
Introduction: Governments are increasingly faced with complicated 
policy choices regarding vaccine use, as indicated by the slow uptake 
of ‘new’ vaccines. 
Methods: We have compiled country-specific databases of 
epidemiologic and economic data for vaccine-preventable disease to 
allow national governments to assess the required financial resources 
and benefits of prevention through vaccination programs for measles, 
hepatitis B (HB), Haemophilus injuenzae type B (Ha) and rotavirus. 
The cost-effectiveness of various vaccines for each country and 
predictors of vaccine uptake were estimated. 
Results: Although new vaccines cost more than traditional 
vaccines, in most countries they would be considered cost-effective 
based on costing less than per capita gross domestic product (GDP) 
per year of life saved. However, financial constraints limit their use. 
Countries where the HB vaccine cost was <0.5% of GDP and where 
routine coverage with DPT was >80% are 6.5 and 3.5 times more 
likely, respectively, to have adopted HB vaccine than countries which 
do not meet these criteria. Disease burden estimates represented a 
relatively low predictor for uptake. 
Conclusions: Quantitative analysis of the health benefits and 
economic implications of vaccination options can help the policy- 
making process and may encourage the appropriate allocation of 
financial resources to fund cost-effective vaccination programs. 
New opportunities to improve outcomes in 
community RTls 
[ E l  A new fluoroquinolone and opportunities to 
improve infection management with 
quinolones 
L. Mandell. Henderson General Hospital, McMaster Medical Unit, 
Hamilton, ON, Canada 
The treatment of patients with lower respiratory tract infections 
(LRTIs), such as acute and chronic bronchitis, acute exacerbations of 
chronic bronchitis and, in particular, community-acquired pneu- 
monia (CAP), is a complex and difficult area. A variety of factors 
make treatment decisions difficult, and physicians must often resort 
to empirical therapy. CAP is not a homogeneous entity; a variety of 
pathogens may be responsible, dependmg upon the patient’s age, the 
presence of co-morbid illnesses, where the infection was acquired, 
and the severity of the illness. Complicating matters further are the 
increase in resistance among various pathogens, particularly Strepto- 
coccuspneumoniae, the growing awareness of the importance of atypical 
pathogens, and the possibility of co-infection. The site of care 
decision is also very important and affects both the types of drugs that 
can be used and the overall costs associated with treatment. Approxi- 
mately 80% of CAP patients may be treated outside the hospital with 
mortality rates of less than 1%; those requiring hospital admission 
have substantially higher mortality rates. Current diagnostic methods 
rely on either the clinical approach or the use of invasive techniques. 
The former relies upon information obtained 6om patient history, 
physical examination and chest X-ray; the latter is dependent upon 
methods such as fiberoptic bronchoscopy. Both have limitations. 
Given these problems, it is clear that empirical therapy is usually 
required. The new fluoroquinolone, trovafloxacin, provides coverage 
against the pathogens of concern, while, at the same time, exhibiting 
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excellent phariiiacokinetic and pharniacodynaniic characteristics that 
ensure its clinical efficacy 
Role of quinolones in acute exacerbations of 
chronic bronchitis 
J. Lorenz. Krt-iskrankriikans Liidensrkeid, h e r e  .4ht. 11, Liidenschrid, 
Germany 
Chronic bronchitis (CB) is one of the most prevalent chronic diseases 
in adults. In general, it is a progressive disorder characterized by acute 
emccrbations (AECB). The role of antibiotics in the management of  
AECB has been under dispute. However, several good clinical studies 
have shown advantages of antibiotic therapy. Hacmopltilns i+enzae 
and pneuiiiococci are the most prevalent pathogens in the sputum of 
patients with AECB, though enterobacteria, Aforaxelh mtarrkalis and 
Cklamydia piienmowiac have been isolated in a proportion of cases. 
During the coune of CB, the likelihood of developing purulent 
AECB increases, and the prevalence of enterobacteria, or even 
Psrudomorzas acrusqinosa infection, increases. Therefore, antibacterial 
treatnient in patients with advanced disease should cover Gram- 
negative bacteria. Older yuinolones, such as ciprofloxacin and 
ofloxacin, have limited use in AECB due to their poor activity against 
Gram-positive bacteria. Recently, extended-spectrum compounds, 
such as ti-ovafloxacin, have been developed. Trovafloxaciri has been 
compared in clinical trials with standard antibiotic agents, such as 
three-times-daily anioxycillin, alone or in combination with 
clavulanic acid, in patients with Aiithonisen class 1 (severe) AECB. 
At a dose of 100 or 200 tng once daily, it has been shown to have 
comparable c1inic.d efficacy and safety to the comparator agents, with 
bettcr eradication of some key pathogens at the 700-iiig dose. The  
antibacterial spectruiii and clinical eficacy of trovafloxacin and other 
compounds has led to the inclusion of the newer yuinolones in new 
European guidelines for the standard treatment of AECB. Trova- 
floxacin is especially appropriate in the treatment of high-risk patients 
with advanced disease. 
Empirical treatment of community-acquired 
pneumonia 
J. Garau. Hmpiral Mirtna dc X w a s s a ,  Dept qf Alrdicine, Barrcloria, 
Spaiii 
Early identification of the causative organisms in conimunity- 
acquired pneumonia (CAP) is rare; antimicrobial therapy tends, 
therefore, to be empirical. The pathogens most frequently associated 
with CAP include: Strrptororcus pnnrmoriiae, Hacmoplzilus influcn:ae 
and Aloraxrlla catarrkalis. However, atypical pathogens, such as 
Le,qionr/la prirumophiia, Cklamydio pnertruoniar and .%lyroplasnza 
pricwnoriiac, also have an important role in the etiology of the disease. 
T h u ,  any antimicrobial agent chosen should ideally have a broad 
spectrum of activity. Penicillins and other beta-lactams are corninonly 
prescribed to treat CAP. There are, however, limitations to their use. 
First, changes have occurred in antibacterial susceptibility patterns 
over the last 10-1 5 yrars. Peiiicillin-re.;istant strains of pneuniococci 
have been reported in all areas of the world. Second, beta-lactamase 
production is increasing among strains of H.  it$ueir;ac and, in 
particular, IZI. catarrkalis. Also, beta-lactams are inactive against 
atypical pathogens; thus, agents such as the iiiacrolides are increas- 
ingly being used. Other agents have therefore been investigated for 
use as enipirical therapy of CAP. Fluoroquinolones have been used 
against respiratory infections with some succe~s. Their use has, 
however, been limited by lack of activity of the older quinolones 
against pneumococci. However, the new-generation fluoro- 
yuinolones, such 3s trovafloxacin and others, are highly actlve agaimt 
pneuiiiococci (including penicillin-resistant strains) ;tiid atypical 
pathogens, while retaining activity against Graiii-negative pathogens. 
Clinical trials have confirmed their efic'icy in the treatnient of CAI', 
and suggest that they are an approprlate alternative choice for 
empirical therapy. 
(s2181 Achieving early hospital discharge with 
community-acquired pneumonia 
M.S. Niederiiim. Divisroii qf Pulmonary arid Critiral C u r  ,\frdicirie, 
L+'itit/irop- Lrnitmiry Hospital, hliticoln, XI; 
In trying to achieve early discharge of pdtients with CAP, we need 
to focus on (1) appropriate hospital admission only for those patients 
who can most benefit; (2)  timely use of the most etrective therapy; 
and (3) early switch to o rd  therapy. Defined risk factors for mortality 
in CAP can be incorporated into a prognostic rule to stratify patients 
and help guide the admission decision. As many as 40"% of liospitaliz- 
ations could be eliminated by using such a rule, although this 
approach riiay lead to some non-admitted patients dying or sub- 
sequently requiring ICU admission. An alternative is to me prog- 
nostication rules (e.g. the British Thoracic Society rule) only to help 
clinicians identify severely ill patients. Optimal therapy of CAP 
requires rapid administration of an effective antibiotic regimen. Data 
show that initial therapy reduces mortality if given within X h of 
admission, and that a B-lactani/macrolide combination leads to a 
lower mortality rate than other regimens. Following a good response 
to initial therapy, 3 \witch to oral agents is necessary, and can typically 
be done by day 3 of hospitalization,. The patient can then be promptly 
discharged, as no benefit s eem to come with observation of oral 
therapy in the hospital. Done routinrly, this may actually reduce 
mortality. New fluoroyuinolones, such as trovafloxacin. i m y  .idd to 
a inore efficient ute of hospital resources in  CAI', due to their broad 
spectruin of activity, once-daily dosing, and high oral bioavailability. 
Trovafloxacin 200 nig O D  has been \howl1 to be a\ effiective as 
standard agents in clinicai studies of hospitalized patients with CAt: 
and has facilitated an early switch to ord therapy. 
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Hantavirus-pathogenesis diagnosis, clinical 
approach 
m] Biology of hantaviruses and diagnosis of 
human infections 
A. Lundkvist', 0. Vapalahti', H .  He i i t t~ne i i~ ,  A. Vaheri'. 
A. Plyusnin'. 'Snadislr hstirirtcfor 1itjkctroir.i Disrose Control, arid 
hlicrobiolog and Xmorbiolo~qy Ceitter, Storkholm, Suider i ;  'Haartniari 
Iastitute, Department cf 1 'iroloqy, Lkivcrsiry qf Heliiiiki, Helsinki; 
'Finnish Fwest Rcsoarrh Institute, I Zutaa, Firilarid 
Several unique hantaviruses hme bren discovered in Eur.isia in recent 
years. Tula (TUL) virus was first detected in hfirrotus arialis and ,Zf. 
rossiacnirridionalis trapped in western Russia and later al\o found in 
Slovakia, the Czech Republic, Austria, Poland and Switzerland. 
Khabarovsk (KBR) virus was detected in ,%I. jwfis trapped in Far- 
Eastern Russia. Topografov (TOP) virus, carried by L e m m n ~  sihiricus, 
has been detected in animals trapped in Siberia. The phylogenetic 
relationships of KBK, TOP and I'numala (PUU) hantaviruses and 
their respective carrier rodents suggest that an exceptional host- 
switch has taken place during the evolution of these viruses. 
